Company Press Releases Back
CytoSorbents to Report Q3 2014 Operating and Financial Results
Wednesday November 5, 2014
MONMOUTH JUNCTION, N.J., Nov. 5, 2014 - CytoSorbents Corporation (CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood purification therapy to prevent or treat life-threatening illnesses in the intensive care unit and in cardiac surgery, will report Q3 2014 financial results after the market close on Wednesday, November 12, 2014.
About CytoSorbents Corporation
CytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q3 2014, provide an update on its up-listing plans, and answer pre-submitted questions as time permits.
Conference Call Details:
Date: Wednesday, November 12, 2014
Time: 4:15 PM Eastern
Participant Dial-In: 719-325-2359
Live Presentation Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1047571
It is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link: https://viavid.webcasts.com/starthere.jsp?ei=1047571
An archived recording of the conference call will be available under the Investor Relations section of the Company's website at http://www.cytosorbents.com/invest.htm
Investors are encouraged to submit their questions in advance as soon as possible to Ms. Amy Vogel at firstname.lastname@example.org
CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to modulate inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to try to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com/
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on March 31, 2014, which is available at http://www.sec.gov.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1910667.
Please Click to Follow us on Facebook and Twitter
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
(732) 329-8885 ext. *825
Source: CytoSorbents Corporation